(2026). Sacituzumab govitecan plus pembrolizumab for advanced triple-negative breast cancer with PD-L1-positive: A cost-effectiveness analysis. Health Economics Review.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
"Sacituzumab Govitecan Plus Pembrolizumab for Advanced Triple-negative Breast Cancer with PD-L1-positive: A Cost-effectiveness Analysis."
Health Economics Review 2026.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
"Sacituzumab Govitecan Plus Pembrolizumab for Advanced Triple-negative Breast Cancer with PD-L1-positive: A Cost-effectiveness Analysis."
Health Economics Review, 2026.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.